Scientia Vascular, a rapidly growing commercial company focused on helping save patients’ lives with a suite of interventional medical devices, has raised $50M of growth equity financing from Vivo Capital, a Palo Alto, CA-headquartered global healthcare investment firm. The financing will be used to accelerate sales, marketing, and new product development in both its core neurovascular stroke market as well as adjacent markets in peripheral vascular and interventional oncology.
“We are excited to partner with Vivo as we embark on our next stage of growth,” says John Lippert, founder and CEO of Scientia. “We’ve had a long-standing vision for enhancing patient treatment, which now can be accelerated with the financing.”
“In the medical device space, Vivo focuses on finding technologically differentiated, founder-owned companies looking to partner with a growth-oriented investment firm with deep expertise in healthcare. We look forward to helping Scientia grow in the years ahead,” states Mahendra Shah, managing director at Vivo Capital.
